Jeffrey Greve, PhD is Co-Founder and Chief Scientific Officer of Kyverna Therapeutics. Prior to Kyverna, he was the founder and Chief Scientific Officer of Delinia, a company that developed a novel protein therapeutic to augment Regulatory T Cells for autoimmune disease, which was acquired by Celgene in 2017. From 2011 to 2013, Jeff served as Vice President of Research at Atyr Pharma.
From 2005 through 2011, Jeff was Executive Director of Stem Cell Sciences at Exelixis, where he was responsible for an alliance with Genentech focused on discovery of Notch Pathway therapeutics and for establishing a drug discovery program centered on stem cell biology. Prior to that, he served as director of Molecular Discovery at Bayer Biotechnology, where he led a group that discovered and advanced into clinical development five novel protein therapeutics in autoimmune, inflammatory, anti-infective, and metabolic diseases. Prior to that, Jeff was a scientist at Molecular Therapeutics, Inc., where he and his colleagues discovered and cloned the human rhinovirus receptor.
Jeff received his BA from Johns Hopkins University, his PhD in Molecular Biology from Washington University, and did a postdoctoral fellowship at Harvard Medical School.